Home LiteratureArticle Details
PMID: 16077016 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform.

Genome research ·Vol. 15 ·No. 8 ·2005-08-00 ·Pages 1168-76

Maris JM, Hii G, Gelfand CA, Varde S, White PS, Rappaport E, Surrey S, Fortina P

Abstract

Many cancers are characterized by chromosomal aberrations that may be predictive of disease outcome. Human neuroblastomas are characterized by somatically acquired copy number changes, including loss of heterozygosity (LOH) at multiple chromosomal loci, and these aberrations are strongly associated with clinical phenotype including patient outcome. We developed a method to assess region-specific LOH by genotyping multiple SNPs simultaneously in DNA from tumor tissues. We identified informative SNPs at an average 293-kb density across nine regions of recurrent LOH in human neuroblastomas. We also identified SNPs in two copy number neutral regions, as well as two regions of copy number gain. SNPs were PCR-amplified in 12-plex reactions and used in solution-phase single-nucleotide extension incorporating tagged dideoxynucleotides. Each extension primer had 5' complementarity to one of 2000 oligonucleotides on a commercially available tag-array platform allowing for solid-phase sorting and identification of individual SNPs. This approach allowed for simultaneous detection of multiple regions of LOH in six human neuroblastoma-derived cell lines, and, more importantly, 14 human neuroblastoma primary tumors. Concordance with conventional genotyping was nearly absolute. Detection of LOH in this assay may not require comparison to matched normal DNAs because of the redundancy of informative SNPs in each region. The customized tag-array system for LOH detection described here is rapid, results in parallel assessment of multiple genomic alterations, and may speed identification of and/or assaying prognostically relevant DNA copy number alterations in many human cancers.

MeSH Terms
Humans Loss of Heterozygosity Nervous System Neoplasms/genetics Neuroblastoma/genetics Oligonucleotide Array Sequence Analysis/methods Polymorphism, Single Nucleotide Reference Values Sensitivity and Specificity Tumor Cells, Cultured
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Maris John M
Division of Oncology, The Children's Hospital of Philadelphia, and Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.
Hii George
Gelfand Craig A
Varde Shobha
White Peter S
Rappaport Eric
Surrey Saul
Fortina Paolo
References (38)
38 references, click to expand
  1. Allelic imbalance on chromosome 5q predicts long-term survival in neuroblastoma.
    Br J Cancer. 1996 Dec;74(12):1855-61 PMID: 8980382
  2. Allelic loss of the short arm of chromosome 4 in neuroblastoma suggests a novel tumour suppressor gene locus.
    Hum Genet. 1996 Jun;97(6):834-7 PMID: 8641706
  3. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study.
    J Natl Cancer Inst. 1997 Mar 5;89(5):373-80 PMID: 9060959
  4. Loss of heterozygosity at chromosome 9p21 in primary neuroblastomas: evidence for two deleted regions.
    Cancer Genet Cytogenet. 1997 Jul 15;96(2):134-9 PMID: 9216721
  5. Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines.
    Cancer Genet Cytogenet. 1997 Sep;97(2):135-42 PMID: 9283597
  6. Analysis of 1;17 translocation breakpoints in neuroblastoma: implications for mapping of neuroblastoma genes.
    Eur J Cancer. 1997 Oct;33(12):1974-8 PMID: 9516836
  7. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.
    J Clin Oncol. 1998 Apr;16(4):1256-64 PMID: 9552023
  8. Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene.
    Br J Cancer. 1998 Jun;77(11):1787-91 PMID: 9667647
  9. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization.
    Genes Chromosomes Cancer. 1998 Oct;23(2):141-52 PMID: 9739017
  10. Loss of DCC expression in neuroblastoma is associated with disease dissemination.
    Clin Cancer Res. 1996 Jul;2(7):1097-102 PMID: 9816273
  11. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.
    Oncogene. 1999 Sep 2;18(35):4948-57 PMID: 10490829
  12. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma.
    Oncogene. 2005 Apr 14;24(16):2684-94 PMID: 15829979
  13. Molecular biology of neuroblastoma.
    J Clin Oncol. 1999 Jul;17(7):2264-79 PMID: 10561284
  14. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study.
    J Clin Oncol. 2000 Mar;18(6):1260-8 PMID: 10715296
  15. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study.
    J Clin Oncol. 2000 May;18(9):1888-99 PMID: 10784629
  16. Parallel genotyping of human SNPs using generic high-density oligonucleotide tag arrays.
    Genome Res. 2000 Jun;10(6):853-60 PMID: 10854416
  17. Coordinate deletion of chromosome 3p and 11q in neuroblastoma detected by comparative genomic hybridization.
    Cancer Genet Cytogenet. 2000 Jul 1;120(1):44-9 PMID: 10913676
  18. Deletion mapping of 14q32 in human neuroblastoma defines an 1,100-kb region of common allelic loss.
    Med Pediatr Oncol. 2000 Dec;35(6):522-5 PMID: 11107107
  19. Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas.
    Med Pediatr Oncol. 2000 Dec;35(6):544-6 PMID: 11107113
  20. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification.
    Int J Cancer. 2001 Mar 1;91(5):680-6 PMID: 11267980
  21. Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma.
    Clin Cancer Res. 2001 May;7(5):1358-61 PMID: 11350906
  22. Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: a pediatric oncology group study.
    Neoplasia. 2001 Mar-Apr;3(2):105-9 PMID: 11420745
  23. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there?
    Med Pediatr Oncol. 2001 Jan;36(1):5-10 PMID: 11464905
  24. Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis.
    Br J Cancer. 2001 Aug 17;85(4):531-7 PMID: 11506492
  25. Neuroblastoma tumour genetics: clinical and biological aspects.
    J Clin Pathol. 2001 Dec;54(12):897-910 PMID: 11729208
  26. Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma.
    Cancer. 2002 May 15;94(10):2756-65 PMID: 12173347
  27. Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13.
    Cancer Res. 2002 Nov 15;62(22):6651-8 PMID: 12438263
  28. Weak linkage at 4p16 to predisposition for human neuroblastoma.
    Oncogene. 2002 Nov 28;21(54):8356-60 PMID: 12447700
  29. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma.
    Clin Cancer Res. 2003 Jan;9(1):52-8 PMID: 12538451
  30. Neuroblastoma: biological insights into a clinical enigma.
    Nat Rev Cancer. 2003 Mar;3(3):203-16 PMID: 12612655
  31. Cancer genes and the pathways they control.
    Nat Med. 2004 Aug;10(8):789-99 PMID: 15286780
  32. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.
    Science. 1984 Jun 8;224(4653):1121-4 PMID: 6719137
  33. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas.
    J Natl Cancer Inst. 1984 Aug;73(2):405-16 PMID: 6589432
  34. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.
    N Engl J Med. 1985 Oct 31;313(18):1111-6 PMID: 4047115
  35. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study.
    J Clin Oncol. 1991 Apr;9(4):581-91 PMID: 2066755
  36. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
    J Clin Oncol. 1993 Aug;11(8):1466-77 PMID: 8336186
  37. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
    N Engl J Med. 1996 Jan 25;334(4):225-30 PMID: 8531999
  38. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization.
    Am J Pathol. 1997 Jan;150(1):81-9 PMID: 9006325
Article Info
Journal
Genome research
Abbr.
Genome Res
ISSN
1088-9051
Published
2005-08-00
Pages
1168-76
Language
English
Region
United States
NLM ID
9518021
PMCID
PMC1182230
Subset
IM
Grants
NCI NIH HHS · R01-CA78545 · United States
NCI NIH HHS · R01 CA078545 · United States
NCI NIH HHS · R33 CA083220 · United States
NHLBI NIH HHS · R01-HL69256 · United States
NCI NIH HHS · R01-CA87847 · United States
NHLBI NIH HHS · R01 HL069256 · United States
NCI NIH HHS · U10 CA098543 · United States
NCI NIH HHS · R33-CA83220 · United States
NCI NIH HHS · U01-CA98543 · United States
NCI NIH HHS · R01 CA087847 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com